Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score

Reduced emotional experience and reduced emotional expression

Philip D Harvey, Jay B. Saoud, Remy Luthringer, Svetlana Moroz, Yuliya Blazhevych, Cristinel Stefanescu, Michael Davidson

Research output: Contribution to journalArticle

Abstract

Background: Recent research has suggested that negative symptoms (NS) can be considered in terms of two different dimensions: reduced expression (expressive deficit) and reduced experience (experiential deficit). Roluperidone, a compound with high affinities for 5 HT2A and sigma2 receptors, has previously shown superiority over placebo on improving NS in a prospective study in patients with schizophrenia. The objective here is to explore the effect of roluperidone compared to placebo, on the 2 domains of the Negative Symptoms. Methods: This was a multi-national Phase 2b trial that enrolled 244 symptomatically stable patients with schizophrenia who had baseline scores ≥20 on the NS subscale of the PANSS. Patients were randomized to daily monotherapy with roluperidone 32 mg, roluperidone 64 mg, or placebo in a 1:1:1 ratio. All enrolled patients were Caucasian, and 137 (56%) were male. The 3 treatment groups were balanced on all demographic and illness-related baseline characteristics. Results: Both doses of roluperidone were superior to placebo on both domains: Reduced Experience (p ≤.006 for the 32 mg; p ≤.001 for the 64 mg) with persistent superiority from Week 2 for the 64 mg dose and Week 8 for the 32 mg dose; Reduced Expression (p ≤.003 for 32 mg; p ≤.001 for 64 mg) with similar persistence. Implications: Both doses of roluperidone previously improved PANSS negative symptoms in general and demonstrated tolerability in stable schizophrenia patients. The post hoc analysis reported here found the drug to work on both the reduced emotional experience and reduced emotional expression sub-scales empirically derived from the PANSS.

Original languageEnglish (US)
JournalSchizophrenia Research
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Placebos
Schizophrenia
Receptor, Serotonin, 5-HT2A
Demography
Prospective Studies
Research
Pharmaceutical Preparations
Therapeutics

Keywords

  • Anhedonia
  • Avolition
  • Negative symptoms
  • Roluperidone
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score : Reduced emotional experience and reduced emotional expression. / Harvey, Philip D; Saoud, Jay B.; Luthringer, Remy; Moroz, Svetlana; Blazhevych, Yuliya; Stefanescu, Cristinel; Davidson, Michael.

In: Schizophrenia Research, 01.01.2019.

Research output: Contribution to journalArticle

Harvey, Philip D ; Saoud, Jay B. ; Luthringer, Remy ; Moroz, Svetlana ; Blazhevych, Yuliya ; Stefanescu, Cristinel ; Davidson, Michael. / Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score : Reduced emotional experience and reduced emotional expression. In: Schizophrenia Research. 2019.
@article{0e623bd6dc3d4b1d9c66ebc64a1ce280,
title = "Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score: Reduced emotional experience and reduced emotional expression",
abstract = "Background: Recent research has suggested that negative symptoms (NS) can be considered in terms of two different dimensions: reduced expression (expressive deficit) and reduced experience (experiential deficit). Roluperidone, a compound with high affinities for 5 HT2A and sigma2 receptors, has previously shown superiority over placebo on improving NS in a prospective study in patients with schizophrenia. The objective here is to explore the effect of roluperidone compared to placebo, on the 2 domains of the Negative Symptoms. Methods: This was a multi-national Phase 2b trial that enrolled 244 symptomatically stable patients with schizophrenia who had baseline scores ≥20 on the NS subscale of the PANSS. Patients were randomized to daily monotherapy with roluperidone 32 mg, roluperidone 64 mg, or placebo in a 1:1:1 ratio. All enrolled patients were Caucasian, and 137 (56{\%}) were male. The 3 treatment groups were balanced on all demographic and illness-related baseline characteristics. Results: Both doses of roluperidone were superior to placebo on both domains: Reduced Experience (p ≤.006 for the 32 mg; p ≤.001 for the 64 mg) with persistent superiority from Week 2 for the 64 mg dose and Week 8 for the 32 mg dose; Reduced Expression (p ≤.003 for 32 mg; p ≤.001 for 64 mg) with similar persistence. Implications: Both doses of roluperidone previously improved PANSS negative symptoms in general and demonstrated tolerability in stable schizophrenia patients. The post hoc analysis reported here found the drug to work on both the reduced emotional experience and reduced emotional expression sub-scales empirically derived from the PANSS.",
keywords = "Anhedonia, Avolition, Negative symptoms, Roluperidone, Schizophrenia",
author = "Harvey, {Philip D} and Saoud, {Jay B.} and Remy Luthringer and Svetlana Moroz and Yuliya Blazhevych and Cristinel Stefanescu and Michael Davidson",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.schres.2019.08.029",
language = "English (US)",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",

}

TY - JOUR

T1 - Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score

T2 - Reduced emotional experience and reduced emotional expression

AU - Harvey, Philip D

AU - Saoud, Jay B.

AU - Luthringer, Remy

AU - Moroz, Svetlana

AU - Blazhevych, Yuliya

AU - Stefanescu, Cristinel

AU - Davidson, Michael

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Recent research has suggested that negative symptoms (NS) can be considered in terms of two different dimensions: reduced expression (expressive deficit) and reduced experience (experiential deficit). Roluperidone, a compound with high affinities for 5 HT2A and sigma2 receptors, has previously shown superiority over placebo on improving NS in a prospective study in patients with schizophrenia. The objective here is to explore the effect of roluperidone compared to placebo, on the 2 domains of the Negative Symptoms. Methods: This was a multi-national Phase 2b trial that enrolled 244 symptomatically stable patients with schizophrenia who had baseline scores ≥20 on the NS subscale of the PANSS. Patients were randomized to daily monotherapy with roluperidone 32 mg, roluperidone 64 mg, or placebo in a 1:1:1 ratio. All enrolled patients were Caucasian, and 137 (56%) were male. The 3 treatment groups were balanced on all demographic and illness-related baseline characteristics. Results: Both doses of roluperidone were superior to placebo on both domains: Reduced Experience (p ≤.006 for the 32 mg; p ≤.001 for the 64 mg) with persistent superiority from Week 2 for the 64 mg dose and Week 8 for the 32 mg dose; Reduced Expression (p ≤.003 for 32 mg; p ≤.001 for 64 mg) with similar persistence. Implications: Both doses of roluperidone previously improved PANSS negative symptoms in general and demonstrated tolerability in stable schizophrenia patients. The post hoc analysis reported here found the drug to work on both the reduced emotional experience and reduced emotional expression sub-scales empirically derived from the PANSS.

AB - Background: Recent research has suggested that negative symptoms (NS) can be considered in terms of two different dimensions: reduced expression (expressive deficit) and reduced experience (experiential deficit). Roluperidone, a compound with high affinities for 5 HT2A and sigma2 receptors, has previously shown superiority over placebo on improving NS in a prospective study in patients with schizophrenia. The objective here is to explore the effect of roluperidone compared to placebo, on the 2 domains of the Negative Symptoms. Methods: This was a multi-national Phase 2b trial that enrolled 244 symptomatically stable patients with schizophrenia who had baseline scores ≥20 on the NS subscale of the PANSS. Patients were randomized to daily monotherapy with roluperidone 32 mg, roluperidone 64 mg, or placebo in a 1:1:1 ratio. All enrolled patients were Caucasian, and 137 (56%) were male. The 3 treatment groups were balanced on all demographic and illness-related baseline characteristics. Results: Both doses of roluperidone were superior to placebo on both domains: Reduced Experience (p ≤.006 for the 32 mg; p ≤.001 for the 64 mg) with persistent superiority from Week 2 for the 64 mg dose and Week 8 for the 32 mg dose; Reduced Expression (p ≤.003 for 32 mg; p ≤.001 for 64 mg) with similar persistence. Implications: Both doses of roluperidone previously improved PANSS negative symptoms in general and demonstrated tolerability in stable schizophrenia patients. The post hoc analysis reported here found the drug to work on both the reduced emotional experience and reduced emotional expression sub-scales empirically derived from the PANSS.

KW - Anhedonia

KW - Avolition

KW - Negative symptoms

KW - Roluperidone

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85071584948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071584948&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2019.08.029

DO - 10.1016/j.schres.2019.08.029

M3 - Article

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

ER -